絞り込み

16548

広告

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.

著者 Yang CJ , Tsai MJ , Hung JY , Lee MH , Tsai YM , Tsai YC , Hsu JF , Liu TC , Huang MS , Chong IW
BMC Pharmacol Toxicol.2017 Dec 13 ; 18(1):82.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (72view , 0users)

Full Text Sources

Medical

Miscellaneous

Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been shown to have better efficacy in the treatment of non-small cell lung cancer harboring EGFR mutations. However, 40 mg daily as the initial dose is often accompanied by serious adverse drug reactions (ADRs) and 28 to 53.3% of patients required a dose reduction. No previous study has compared the clinical efficacy and ADRs of different initial doses (40 mg vs. 30 mg daily) of afatinib in lung cancer treatment.
PMID: 29237484 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード